PCA3Plus™ the Next Generation Genetic Test for Prostate Cancer Risk: Exclusively from Bostwick Laboratories, Inc.
May 4, 2006 - RICHMOND, Va. -- Bostwick Laboratories, Inc. announces the immediate availability of PCA3Plus(TM), a urine-based genetic test for prostate cancer risk, exclusively from Bostwick Laboratories, Inc.
PCA3Plus(TM) detects PCA3, a specific gene that is highly expressed in prostate cancer. No other human tissues express PCA3.
"We are pleased to be the first to provide the innovative PCA3Plus(TM) test for men at risk for prostate cancer. This test is the second generation of the hugely successful uPM3(TM) test, the first genetic test for prostate cancer risk available exclusively by Bostwick Laboratories, Inc. since 2004. PCA3Plus(TM) uses technology that provides even greater reproducibility than uPM3(TM)," said David G. Bostwick, MD, MBA, Chief Executive Officer and Chief Medical Officer.
PCA3Plus(TM) tests for prostate cancer cells that are shed into the urine. The urine sample is sent to Bostwick Laboratories, Inc. to be tested for genetic expression of the PCA3 gene. If the sample is positive for PCA3, then the patient has a very high likelihood of having prostatic cancer.
PCA3Plus(TM), validated by Bostwick Laboratories, Inc., predicts prostate cancer with a sensitivity of 91%.
Bostwick Laboratories, Inc. is an international reference laboratory that specializes in state-of-the-art testing. It focuses on urologic diseases such as prostate cancer.
PCA3Plus(TM) has not been cleared or approved by the FDA, and is based upon reagents manufactured by Gen-Probe (San Diego, California). PCA3Plus(TM) is a trademark of Bostwick Laboratories, Inc. uPM3(TM) is a trademark of DiagnoCure (Quebec City, Quebec, Canada).
For More Information, Contact: Holly Moloney, Marketing Specialist Bostwick Laboratories, Inc. 804-967-9225 (voice) 804-545-9751 (fax) [email protected]
